ID   NAA10_HUMAN             Reviewed;         235 AA.
AC   P41227; A6NM98;
DT   01-FEB-1995, integrated into UniProtKB/Swiss-Prot.
DT   01-FEB-1995, sequence version 1.
DT   10-MAY-2017, entry version 168.
DE   RecName: Full=N-alpha-acetyltransferase 10;
DE            EC=2.3.1.255 {ECO:0000269|PubMed:15496142};
DE   AltName: Full=N-terminal acetyltransferase complex ARD1 subunit homolog A;
DE   AltName: Full=NatA catalytic subunit Naa10;
GN   Name=NAA10; Synonyms=ARD1, ARD1A, TE2;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=7981673; DOI=10.1093/hmg/3.7.1061;
RA   Tribioli C., Mancini M., Plassart E., Bione S., Rivella S., Sala C.,
RA   Torri G., Toniolo D.;
RT   "Isolation of new genes in distal Xq28: transcriptional map and
RT   identification of a human homologue of the ARD1 N-acetyl transferase
RT   of Saccharomyces cerevisiae.";
RL   Hum. Mol. Genet. 3:1061-1068(1994).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), IDENTIFICATION BY MASS
RP   SPECTROMETRY, FUNCTION, CATALYTIC ACTIVITY, SUBCELLULAR LOCATION, AND
RP   INTERACTION WITH NAA15 AND RIBOSOMAL PROTEINS.
RC   TISSUE=Thyroid carcinoma;
RX   PubMed=15496142; DOI=10.1042/BJ20041071;
RA   Arnesen T., Anderson D., Baldersheim C., Lanotte M., Varhaug J.E.,
RA   Lillehaug J.R.;
RT   "Identification and characterization of the human ARD1-NATH protein
RT   acetyltransferase complex.";
RL   Biochem. J. 386:433-443(2005).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15772651; DOI=10.1038/nature03440;
RA   Ross M.T., Grafham D.V., Coffey A.J., Scherer S., McLay K., Muzny D.,
RA   Platzer M., Howell G.R., Burrows C., Bird C.P., Frankish A.,
RA   Lovell F.L., Howe K.L., Ashurst J.L., Fulton R.S., Sudbrak R., Wen G.,
RA   Jones M.C., Hurles M.E., Andrews T.D., Scott C.E., Searle S.,
RA   Ramser J., Whittaker A., Deadman R., Carter N.P., Hunt S.E., Chen R.,
RA   Cree A., Gunaratne P., Havlak P., Hodgson A., Metzker M.L.,
RA   Richards S., Scott G., Steffen D., Sodergren E., Wheeler D.A.,
RA   Worley K.C., Ainscough R., Ambrose K.D., Ansari-Lari M.A., Aradhya S.,
RA   Ashwell R.I., Babbage A.K., Bagguley C.L., Ballabio A., Banerjee R.,
RA   Barker G.E., Barlow K.F., Barrett I.P., Bates K.N., Beare D.M.,
RA   Beasley H., Beasley O., Beck A., Bethel G., Blechschmidt K., Brady N.,
RA   Bray-Allen S., Bridgeman A.M., Brown A.J., Brown M.J., Bonnin D.,
RA   Bruford E.A., Buhay C., Burch P., Burford D., Burgess J., Burrill W.,
RA   Burton J., Bye J.M., Carder C., Carrel L., Chako J., Chapman J.C.,
RA   Chavez D., Chen E., Chen G., Chen Y., Chen Z., Chinault C.,
RA   Ciccodicola A., Clark S.Y., Clarke G., Clee C.M., Clegg S.,
RA   Clerc-Blankenburg K., Clifford K., Cobley V., Cole C.G., Conquer J.S.,
RA   Corby N., Connor R.E., David R., Davies J., Davis C., Davis J.,
RA   Delgado O., Deshazo D., Dhami P., Ding Y., Dinh H., Dodsworth S.,
RA   Draper H., Dugan-Rocha S., Dunham A., Dunn M., Durbin K.J., Dutta I.,
RA   Eades T., Ellwood M., Emery-Cohen A., Errington H., Evans K.L.,
RA   Faulkner L., Francis F., Frankland J., Fraser A.E., Galgoczy P.,
RA   Gilbert J., Gill R., Gloeckner G., Gregory S.G., Gribble S.,
RA   Griffiths C., Grocock R., Gu Y., Gwilliam R., Hamilton C., Hart E.A.,
RA   Hawes A., Heath P.D., Heitmann K., Hennig S., Hernandez J.,
RA   Hinzmann B., Ho S., Hoffs M., Howden P.J., Huckle E.J., Hume J.,
RA   Hunt P.J., Hunt A.R., Isherwood J., Jacob L., Johnson D., Jones S.,
RA   de Jong P.J., Joseph S.S., Keenan S., Kelly S., Kershaw J.K., Khan Z.,
RA   Kioschis P., Klages S., Knights A.J., Kosiura A., Kovar-Smith C.,
RA   Laird G.K., Langford C., Lawlor S., Leversha M., Lewis L., Liu W.,
RA   Lloyd C., Lloyd D.M., Loulseged H., Loveland J.E., Lovell J.D.,
RA   Lozado R., Lu J., Lyne R., Ma J., Maheshwari M., Matthews L.H.,
RA   McDowall J., McLaren S., McMurray A., Meidl P., Meitinger T.,
RA   Milne S., Miner G., Mistry S.L., Morgan M., Morris S., Mueller I.,
RA   Mullikin J.C., Nguyen N., Nordsiek G., Nyakatura G., O'dell C.N.,
RA   Okwuonu G., Palmer S., Pandian R., Parker D., Parrish J.,
RA   Pasternak S., Patel D., Pearce A.V., Pearson D.M., Pelan S.E.,
RA   Perez L., Porter K.M., Ramsey Y., Reichwald K., Rhodes S.,
RA   Ridler K.A., Schlessinger D., Schueler M.G., Sehra H.K.,
RA   Shaw-Smith C., Shen H., Sheridan E.M., Shownkeen R., Skuce C.D.,
RA   Smith M.L., Sotheran E.C., Steingruber H.E., Steward C.A., Storey R.,
RA   Swann R.M., Swarbreck D., Tabor P.E., Taudien S., Taylor T.,
RA   Teague B., Thomas K., Thorpe A., Timms K., Tracey A., Trevanion S.,
RA   Tromans A.C., d'Urso M., Verduzco D., Villasana D., Waldron L.,
RA   Wall M., Wang Q., Warren J., Warry G.L., Wei X., West A.,
RA   Whitehead S.L., Whiteley M.N., Wilkinson J.E., Willey D.L.,
RA   Williams G., Williams L., Williamson A., Williamson H., Wilming L.,
RA   Woodmansey R.L., Wray P.W., Yen J., Zhang J., Zhou J., Zoghbi H.,
RA   Zorilla S., Buck D., Reinhardt R., Poustka A., Rosenthal A.,
RA   Lehrach H., Meindl A., Minx P.J., Hillier L.W., Willard H.F.,
RA   Wilson R.K., Waterston R.H., Rice C.M., Vaudin M., Coulson A.,
RA   Nelson D.L., Weinstock G., Sulston J.E., Durbin R.M., Hubbard T.,
RA   Gibbs R.A., Beck S., Rogers J., Bentley D.R.;
RT   "The DNA sequence of the human X chromosome.";
RL   Nature 434:325-337(2005).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Lung;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   INTERACTION WITH HIF1A, FUNCTION, TISSUE SPECIFICITY, AND SUBCELLULAR
RP   LOCATION.
RX   PubMed=12464182; DOI=10.1016/S0092-8674(02)01085-1;
RA   Jeong J.-W., Bae M.-K., Ahn M.-Y., Kim S.-H., Sohn T.-K., Bae M.-H.,
RA   Yoo M.-A., Song E.-J., Lee K.-J., Kim K.-W.;
RT   "Regulation and destabilization of HIF-1alpha by ARD1-mediated
RT   acetylation.";
RL   Cell 111:709-720(2002).
RN   [7]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-182, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=17081983; DOI=10.1016/j.cell.2006.09.026;
RA   Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P.,
RA   Mann M.;
RT   "Global, in vivo, and site-specific phosphorylation dynamics in
RT   signaling networks.";
RL   Cell 127:635-648(2006).
RN   [8]
RP   INTERACTION WITH NAA50.
RX   PubMed=16507339; DOI=10.1016/j.gene.2005.12.008;
RA   Arnesen T., Anderson D., Torsvik J., Halseth H.B., Varhaug J.E.,
RA   Lillehaug J.R.;
RT   "Cloning and characterization of hNAT5/hSAN: an evolutionarily
RT   conserved component of the NatA protein N-alpha-acetyltransferase
RT   complex.";
RL   Gene 371:291-295(2006).
RN   [9]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-186 AND SER-205, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [10]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT MET-1, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J.,
RA   Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in
RT   a refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [11]
RP   INTERACTION WITH NAA16.
RX   PubMed=19480662; DOI=10.1186/1471-2091-10-15;
RA   Arnesen T., Gromyko D., Kagabo D., Betts M.J., Starheim K.K.,
RA   Varhaug J.E., Anderson D., Lillehaug J.R.;
RT   "A novel human NatA Nalpha-terminal acetyltransferase complex:
RT   hNaa16p-hNaa10p (hNat2-hArd1).";
RL   BMC Biochem. 10:15-15(2009).
RN   [12]
RP   NOMENCLATURE.
RX   PubMed=19660095; DOI=10.1186/1753-6561-3-S6-S2;
RA   Polevoda B., Arnesen T., Sherman F.;
RT   "A synopsis of eukaryotic Nalpha-terminal acetyltransferases:
RT   nomenclature, subunits and substrates.";
RL   BMC Proc. 3:S2-S2(2009).
RN   [13]
RP   PHOSPHORYLATION AT SER-209 BY IKBKB, MUTAGENESIS OF SER-209, AND
RP   INTERACTION WITH IKBKB.
RX   PubMed=19716809; DOI=10.1016/j.bbrc.2009.08.127;
RA   Kuo H.P., Lee D.F., Xia W., Lai C.C., Li L.Y., Hung M.C.;
RT   "Phosphorylation of ARD1 by IKKbeta contributes to its destabilization
RT   and degradation.";
RL   Biochem. Biophys. Res. Commun. 389:156-161(2009).
RN   [14]
RP   FUNCTION, AND INTERACTION WITH MYLK.
RX   PubMed=19826488; DOI=10.1371/journal.pone.0007451;
RA   Shin D.H., Chun Y.-S., Lee K.-H., Shin H.-W., Park J.-W.;
RT   "Arrest defective-1 controls tumor cell behavior by acetylating myosin
RT   light chain kinase.";
RL   PLoS ONE 4:E7451-E7451(2009).
RN   [15]
RP   SUBUNIT.
RX   PubMed=20154145; DOI=10.1128/MCB.01199-09;
RA   Arnesen T., Starheim K.K., Van Damme P., Evjenth R., Dinh H.,
RA   Betts M.J., Ryningen A., Vandekerckhove J., Gevaert K., Anderson D.;
RT   "The chaperone-like protein HYPK acts together with NatA in
RT   cotranslational N-terminal acetylation and prevention of Huntingtin
RT   aggregation.";
RL   Mol. Cell. Biol. 30:1898-1909(2010).
RN   [16]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-182; SER-205; SER-213
RP   AND SER-216, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
RA   Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full
RT   phosphorylation site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [17]
RP   INTERACTION WITH TSC2, AND FUNCTION IN ACETYLATION OF TSC2.
RX   PubMed=20145209; DOI=10.1126/scisignal.2000590;
RA   Kuo H.P., Lee D.F., Chen C.T., Liu M., Chou C.K., Lee H.J., Du Y.,
RA   Xie X., Wei Y., Xia W., Weihua Z., Yang J.Y., Yen C.J., Huang T.H.,
RA   Tan M., Xing G., Zhao Y., Lin C.H., Tsai S.F., Fidler I.J., Hung M.C.;
RT   "ARD1 stabilization of TSC2 suppresses tumorigenesis through the mTOR
RT   signaling pathway.";
RL   Sci. Signal. 3:RA9-RA9(2010).
RN   [18]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [19]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-182 AND SER-205, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J.,
RA   Johansen P.T., Kratchmarova I., Kassem M., Mann M., Olsen J.V.,
RA   Blagoev B.;
RT   "System-wide temporal characterization of the proteome and
RT   phosphoproteome of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [20]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-182; SER-186 AND
RP   SER-205, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [21]
RP   INVOLVEMENT IN MCOPS1.
RX   PubMed=24431331; DOI=10.1136/jmedgenet-2013-101660;
RA   Esmailpour T., Riazifar H., Liu L., Donkervoort S., Huang V.H.,
RA   Madaan S., Shoucri B.M., Busch A., Wu J., Towbin A., Chadwick R.B.,
RA   Sequeira A., Vawter M.P., Sun G., Johnston J.J., Biesecker L.G.,
RA   Kawaguchi R., Sun H., Kimonis V., Huang T.;
RT   "A splice donor mutation in NAA10 results in the dysregulation of the
RT   retinoic acid signalling pathway and causes Lenz microphthalmia
RT   syndrome.";
RL   J. Med. Genet. 51:185-196(2014).
RN   [22]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-186, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [23]
RP   SUBCELLULAR LOCATION.
RX   PubMed=25732826; DOI=10.1016/j.celrep.2015.01.053;
RA   Aksnes H., Van Damme P., Goris M., Starheim K.K., Marie M.,
RA   Stoeve S.I., Hoel C., Kalvik T.V., Hole K., Glomnes N., Furnes C.,
RA   Ljostveit S., Ziegler M., Niere M., Gevaert K., Arnesen T.;
RT   "An organellar nalpha-acetyltransferase, naa60, acetylates cytosolic N
RT   termini of transmembrane proteins and maintains Golgi integrity.";
RL   Cell Rep. 10:1362-1374(2015).
RN   [24]
RP   FUNCTION, INTERACTION WITH HSPA1A AND HSPA1B, ACETYLATION AT LYS-136,
RP   AND MUTAGENESIS OF LYS-136.
RX   PubMed=27708256; DOI=10.1038/ncomms12882;
RA   Seo J.H., Park J.H., Lee E.J., Vo T.T., Choi H., Kim J.Y., Jang J.K.,
RA   Wee H.J., Lee H.S., Jang S.H., Park Z.Y., Jeong J., Lee K.J.,
RA   Seok S.H., Park J.Y., Lee B.J., Lee M.N., Oh G.T., Kim K.W.;
RT   "ARD1-mediated Hsp70 acetylation balances stress-induced protein
RT   refolding and degradation.";
RL   Nat. Commun. 7:12882-12882(2016).
RN   [25]
RP   VARIANT NATD PRO-37, AND CHARACTERIZATION OF VARIANT NATD PRO-37.
RX   PubMed=21700266; DOI=10.1016/j.ajhg.2011.05.017;
RA   Rope A.F., Wang K., Evjenth R., Xing J., Johnston J.J., Swensen J.J.,
RA   Johnson W.E., Moore B., Huff C.D., Bird L.M., Carey J.C., Opitz J.M.,
RA   Stevens C.A., Jiang T., Schank C., Fain H.D., Robison R., Dalley B.,
RA   Chin S., South S.T., Pysher T.J., Jorde L.B., Hakonarson H.,
RA   Lillehaug J.R., Biesecker L.G., Yandell M., Arnesen T., Lyon G.J.;
RT   "Using VAAST to identify an X-linked disorder resulting in lethality
RT   in male infants due to N-terminal acetyltransferase deficiency.";
RL   Am. J. Hum. Genet. 89:28-43(2011).
RN   [26]
RP   VARIANT NATD SER-43, AND CHARACTERIZATION OF VARIANT NATD SER-43.
RX   PubMed=26522270; DOI=10.1038/srep16022;
RA   Casey J.P., Stoeve S.I., McGorrian C., Galvin J., Blenski M.,
RA   Dunne A., Ennis S., Brett F., King M.D., Arnesen T., Lynch S.A.;
RT   "NAA10 mutation causing a novel intellectual disability syndrome with
RT   Long QT due to N-terminal acetyltransferase impairment.";
RL   Sci. Rep. 5:16022-16022(2015).
CC   -!- FUNCTION: Catalytic subunit of the N-terminal acetyltransferase A
CC       (NatA) complex which displays alpha (N-terminal) acetyltransferase
CC       activity. The NAT activity may be important for vascular,
CC       hematopoietic and neuronal growth and development. Without NAA15,
CC       displays epsilon (internal) acetyltransferase activity towards
CC       HIF1A, thereby promoting its degradation. Represses MYLK kinase
CC       activity by acetylation, and thus represses tumor cell migration.
CC       Acetylates, and stabilizes TSC2, thereby repressing mTOR activity
CC       and suppressing cancer development (PubMed:12464182,
CC       PubMed:15496142, PubMed:19826488, PubMed:20145209). Acetylates
CC       HSPA1A and HSPA1B at 'Lys-77' which enhances its chaperone
CC       activity and leads to preferential binding to co-chaperone HOPX
CC       (PubMed:27708256). {ECO:0000269|PubMed:12464182,
CC       ECO:0000269|PubMed:15496142, ECO:0000269|PubMed:19826488,
CC       ECO:0000269|PubMed:20145209, ECO:0000269|PubMed:27708256}.
CC   -!- CATALYTIC ACTIVITY: Acetyl-CoA + an N-terminal-glycyl-[protein] =
CC       an N-terminal-N(alpha)-acetyl-glycyl-[protein] + CoA.
CC       {ECO:0000269|PubMed:15496142}.
CC   -!- CATALYTIC ACTIVITY: Acetyl-CoA + an N-terminal-L-alanyl-[protein]
CC       = an N-terminal-N(alpha)-acetyl-L-alanyl-[protein] + CoA.
CC       {ECO:0000269|PubMed:15496142}.
CC   -!- CATALYTIC ACTIVITY: Acetyl-CoA + an N-terminal-L-seryl-[protein] =
CC       an N-terminal-N(alpha)-acetyl-L-seryl-[protein] + CoA.
CC       {ECO:0000269|PubMed:15496142}.
CC   -!- CATALYTIC ACTIVITY: Acetyl-CoA + an N-terminal-L-valyl-[protein] =
CC       an N-terminal-N(alpha)-acetyl-L-valyl-[protein] + CoA.
CC       {ECO:0000269|PubMed:15496142}.
CC   -!- CATALYTIC ACTIVITY: Acetyl-CoA + an N-terminal-L-cysteinyl-
CC       [protein] = an N-terminal-N(alpha)-acetyl-L-cysteinyl-[protein] +
CC       CoA. {ECO:0000269|PubMed:15496142}.
CC   -!- CATALYTIC ACTIVITY: Acetyl-CoA + an N-terminal-L-threonyl-
CC       [protein] = an N-terminal-N(alpha)-acetyl-L-threonyl-[protein] +
CC       CoA. {ECO:0000269|PubMed:15496142}.
CC   -!- SUBUNIT: Component of the N-terminal acetyltransferase A (NatA)
CC       complex composed of NAA10 and NAA15 or NAA16 (PubMed:20154145).
CC       Interacts with HIF1A (via its ODD domain); the interaction
CC       increases HIF1A protein stability during normoxia, an down-
CC       regulates it when induced by hypoxia (PubMed:12464182). Interacts
CC       with NAA50 and with the ribosome (PubMed:16507339). Binds to MYLK
CC       (PubMed:19826488). Associates with HYPK when in complex with NAA15
CC       (PubMed:20154145). Interacts with NAA15 (PubMed:15496142).
CC       Interacts with NAA16 (PubMed:19480662). Interacts (via its C-
CC       terminal domain) with TSC2, leading to its acetylation
CC       (PubMed:20145209). Interacts with NAA15 (PubMed:15496142).
CC       Interacts with NAA16 (PubMed:19480662). Interacts with IKBKB
CC       (PubMed:19716809). Interacts with HSPA1A and HSPA1B leading to its
CC       acetylation (PubMed:27708256). {ECO:0000269|PubMed:12464182,
CC       ECO:0000269|PubMed:15496142, ECO:0000269|PubMed:16507339,
CC       ECO:0000269|PubMed:19480662, ECO:0000269|PubMed:19716809,
CC       ECO:0000269|PubMed:19826488, ECO:0000269|PubMed:20145209,
CC       ECO:0000269|PubMed:20154145, ECO:0000269|PubMed:27708256}.
CC   -!- INTERACTION:
CC       Q15052:ARHGEF6; NbExp=3; IntAct=EBI-747693, EBI-1642523;
CC       Q14155:ARHGEF7; NbExp=3; IntAct=EBI-747693, EBI-717515;
CC       O55043:Arhgef7 (xeno); NbExp=3; IntAct=EBI-747693, EBI-3649585;
CC       Q6W2J9-4:BCOR; NbExp=3; IntAct=EBI-747693, EBI-10208579;
CC       Q13137:CALCOCO2; NbExp=5; IntAct=EBI-747693, EBI-739580;
CC       Q9C0F1:CEP44; NbExp=3; IntAct=EBI-747693, EBI-744115;
CC       A2ABF9:EHMT2; NbExp=3; IntAct=EBI-747693, EBI-10174566;
CC       Q6UN15:FIP1L1; NbExp=3; IntAct=EBI-747693, EBI-1021914;
CC       Q92845:KIFAP3; NbExp=5; IntAct=EBI-747693, EBI-954040;
CC       P60370:KRTAP10-5; NbExp=3; IntAct=EBI-747693, EBI-10172150;
CC       P60409:KRTAP10-7; NbExp=3; IntAct=EBI-747693, EBI-10172290;
CC       A4D127:MEOX2; NbExp=5; IntAct=EBI-747693, EBI-10172134;
CC       Q9GZZ1:NAA50; NbExp=2; IntAct=EBI-747693, EBI-1052523;
CC       Q5VU43:PDE4DIP; NbExp=3; IntAct=EBI-747693, EBI-1105124;
CC       Q96QF0:RAB3IP; NbExp=3; IntAct=EBI-747693, EBI-747844;
CC       Q9BYM8:RBCK1; NbExp=3; IntAct=EBI-747693, EBI-2340624;
CC       Q9Y2D8:SSX2IP; NbExp=3; IntAct=EBI-747693, EBI-2212028;
CC       O43829:ZBTB14; NbExp=5; IntAct=EBI-747693, EBI-10176632;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:12464182,
CC       ECO:0000269|PubMed:25732826}. Nucleus
CC       {ECO:0000269|PubMed:12464182, ECO:0000269|PubMed:15496142,
CC       ECO:0000269|PubMed:25732826}. Note=Also present in the free
CC       cytosolic and cytoskeleton-bound polysomes.
CC       {ECO:0000269|PubMed:15496142}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=P41227-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P41227-2; Sequence=VSP_046205, VSP_046206;
CC   -!- TISSUE SPECIFICITY: Ubiquitous. {ECO:0000269|PubMed:12464182}.
CC   -!- PTM: Cleaved by caspases during apoptosis.
CC   -!- PTM: Phosphorylation by IKBKB/IKKB at Ser-209 promotes its
CC       proteasome-mediated degradation. {ECO:0000269|PubMed:19716809}.
CC   -!- PTM: Autoacetylated at Lys-136 which stimulates its catalytic
CC       activity. {ECO:0000269|PubMed:27708256}.
CC   -!- DISEASE: N-terminal acetyltransferase deficiency (NATD)
CC       [MIM:300855]: An enzymatic deficiency resulting in postnatal
CC       growth failure with severe delays and dysmorphic features. It is
CC       clinically characterized by wrinkled forehead, prominent eyes,
CC       widely opened anterior and posterior fontanels, downsloping
CC       palpebral fissures, thickened lids, large ears, flared nares,
CC       hypoplastic alae, short columella, protruding upper lip, and
CC       microretrognathia. There are also delayed closing of fontanels and
CC       broad great toes. Skin is characterized by redundancy or laxity
CC       with minimal subcutaneous fat, cutaneous capillary malformations,
CC       and very fine hair and eyebrows. Death results from cardiogenic
CC       shock following arrhythmia. {ECO:0000269|PubMed:21700266,
CC       ECO:0000269|PubMed:26522270}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- DISEASE: Microphthalmia, syndromic, 1 (MCOPS1) [MIM:309800]: A
CC       rare syndrome defined by the canonical features of unilateral or
CC       bilateral microphthalmia or anophthalmia and defects in the
CC       skeletal and genitourinary systems. Microphthalmia is a disorder
CC       of eye formation, ranging from small size of a single eye to
CC       complete bilateral absence of ocular tissues (anophthalmia). In
CC       many cases, microphthalmia/anophthalmia occurs in association with
CC       syndromes that include non-ocular abnormalities. Anomalies of the
CC       digits, teeth, and ears are hallmarks of MCOPS1. Intellectual
CC       disability ranges from mild to severe, with self-mutilating
CC       behaviors and seizures in severely affected MCOPS1 individuals.
CC       {ECO:0000269|PubMed:24431331}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the acetyltransferase family. ARD1
CC       subfamily. {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; X77588; CAA54691.1; -; mRNA.
DR   EMBL; U52112; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471172; EAW72774.1; -; Genomic_DNA.
DR   EMBL; BC000308; AAH00308.1; -; mRNA.
DR   EMBL; BC019312; AAH19312.1; -; mRNA.
DR   CCDS; CCDS14737.1; -. [P41227-1]
DR   CCDS; CCDS59179.1; -. [P41227-2]
DR   PIR; I38333; I38333.
DR   RefSeq; NP_001243048.1; NM_001256119.1. [P41227-2]
DR   RefSeq; NP_003482.1; NM_003491.3. [P41227-1]
DR   UniGene; Hs.433291; -.
DR   ProteinModelPortal; P41227; -.
DR   SMR; P41227; -.
DR   BioGrid; 113881; 57.
DR   IntAct; P41227; 49.
DR   MINT; MINT-1499850; -.
DR   STRING; 9606.ENSP00000417763; -.
DR   iPTMnet; P41227; -.
DR   PhosphoSitePlus; P41227; -.
DR   BioMuta; NAA10; -.
DR   DMDM; 728880; -.
DR   EPD; P41227; -.
DR   MaxQB; P41227; -.
DR   PaxDb; P41227; -.
DR   PeptideAtlas; P41227; -.
DR   PRIDE; P41227; -.
DR   TopDownProteomics; P41227-1; -. [P41227-1]
DR   DNASU; 8260; -.
DR   Ensembl; ENST00000370009; ENSP00000359026; ENSG00000102030. [P41227-2]
DR   Ensembl; ENST00000464845; ENSP00000417763; ENSG00000102030. [P41227-1]
DR   GeneID; 8260; -.
DR   KEGG; hsa:8260; -.
DR   UCSC; uc004fjm.3; human. [P41227-1]
DR   CTD; 8260; -.
DR   DisGeNET; 8260; -.
DR   GeneCards; NAA10; -.
DR   HGNC; HGNC:18704; NAA10.
DR   HPA; CAB006269; -.
DR   HPA; HPA030711; -.
DR   MalaCards; NAA10; -.
DR   MIM; 300013; gene.
DR   MIM; 300855; phenotype.
DR   MIM; 309800; phenotype.
DR   neXtProt; NX_P41227; -.
DR   OpenTargets; ENSG00000102030; -.
DR   Orphanet; 568; Microphthalmia, Lenz type.
DR   Orphanet; 276432; Premature aging appearance-developmental delay-cardiac arrhythmia syndrome.
DR   PharmGKB; PA38648; -.
DR   eggNOG; KOG3235; Eukaryota.
DR   eggNOG; COG0456; LUCA.
DR   GeneTree; ENSGT00550000074803; -.
DR   HOGENOM; HOG000078523; -.
DR   HOVERGEN; HBG050561; -.
DR   InParanoid; P41227; -.
DR   KO; K20791; -.
DR   OrthoDB; EOG091G0JI1; -.
DR   PhylomeDB; P41227; -.
DR   TreeFam; TF300078; -.
DR   ChiTaRS; NAA10; human.
DR   GeneWiki; ARD1A; -.
DR   GenomeRNAi; 8260; -.
DR   PRO; PR:P41227; -.
DR   Proteomes; UP000005640; Chromosome X.
DR   Bgee; ENSG00000102030; -.
DR   CleanEx; HS_ARD1A; -.
DR   ExpressionAtlas; P41227; baseline and differential.
DR   Genevisible; P41227; HS.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0022626; C:cytosolic ribosome; IBA:GO_Central.
DR   GO; GO:0005622; C:intracellular; IDA:LIFEdb.
DR   GO; GO:0016020; C:membrane; IDA:UniProtKB.
DR   GO; GO:0031415; C:NatA complex; IDA:UniProtKB.
DR   GO; GO:0005730; C:nucleolus; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0008080; F:N-acetyltransferase activity; TAS:ProtInc.
DR   GO; GO:1990190; F:peptide-glutamate-N-acetyltransferase activity; IBA:GO_Central.
DR   GO; GO:1990189; F:peptide-serine-N-acetyltransferase activity; IBA:GO_Central.
DR   GO; GO:0006323; P:DNA packaging; TAS:ProtInc.
DR   GO; GO:0006475; P:internal protein amino acid acetylation; TAS:ProtInc.
DR   GO; GO:0018002; P:N-terminal peptidyl-glutamic acid acetylation; IBA:GO_Central.
DR   GO; GO:0017198; P:N-terminal peptidyl-serine acetylation; IBA:GO_Central.
DR   GO; GO:0006474; P:N-terminal protein amino acid acetylation; IDA:UniProtKB.
DR   GO; GO:0006473; P:protein acetylation; IDA:UniProtKB.
DR   InterPro; IPR016181; Acyl_CoA_acyltransferase.
DR   InterPro; IPR000182; GNAT_dom.
DR   Pfam; PF00583; Acetyltransf_1; 1.
DR   SUPFAM; SSF55729; SSF55729; 1.
DR   PROSITE; PS51186; GNAT; 1.
PE   1: Evidence at protein level;
KW   Acetylation; Acyltransferase; Alternative splicing; Complete proteome;
KW   Cytoplasm; Disease mutation; Microphthalmia; Nucleus; Phosphoprotein;
KW   Reference proteome; Transferase.
FT   CHAIN         1    235       N-alpha-acetyltransferase 10.
FT                                /FTId=PRO_0000074532.
FT   DOMAIN        1    152       N-acetyltransferase.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00532}.
FT   REGION        1     58       Interaction with NAA15.
FT                                {ECO:0000269|PubMed:15496142}.
FT   MOD_RES       1      1       N-acetylmethionine.
FT                                {ECO:0000244|PubMed:19413330}.
FT   MOD_RES     136    136       N6-acetyllysine; by autocatalysis.
FT                                {ECO:0000269|PubMed:27708256}.
FT   MOD_RES     182    182       Phosphoserine.
FT                                {ECO:0000244|PubMed:17081983,
FT                                ECO:0000244|PubMed:20068231,
FT                                ECO:0000244|PubMed:21406692,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES     186    186       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:23186163,
FT                                ECO:0000244|PubMed:24275569}.
FT   MOD_RES     205    205       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:20068231,
FT                                ECO:0000244|PubMed:21406692,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES     209    209       Phosphoserine; by IKKB.
FT                                {ECO:0000269|PubMed:19716809}.
FT   MOD_RES     213    213       Phosphoserine.
FT                                {ECO:0000244|PubMed:20068231}.
FT   MOD_RES     216    216       Phosphoserine.
FT                                {ECO:0000244|PubMed:20068231}.
FT   VAR_SEQ     114    128       Missing (in isoform 2). {ECO:0000305}.
FT                                /FTId=VSP_046205.
FT   VAR_SEQ     129    129       Q -> R (in isoform 2). {ECO:0000305}.
FT                                /FTId=VSP_046206.
FT   VARIANT      37     37       S -> P (in NATD; in vitro assays of
FT                                protein function demonstrates 60 to 80%
FT                                reduction in NAT activity of the mutant
FT                                protein toward the in vivo substrate
FT                                RPP30 protein; the activity toward the
FT                                substrate HMGA1 protein is reduced by
FT                                only 20%; dbSNP:rs387906701).
FT                                {ECO:0000269|PubMed:21700266}.
FT                                /FTId=VAR_066652.
FT   VARIANT      43     43       Y -> S (in NATD; decreased protein
FT                                stability; strong decrease in N-terminal
FT                                acetylation activity in vitro;
FT                                dbSNP:rs863225427).
FT                                {ECO:0000269|PubMed:26522270}.
FT                                /FTId=VAR_075206.
FT   MUTAGEN     136    136       K->R: Loss of its ability to acetylate
FT                                HSPA1A and HSPA1B.
FT                                {ECO:0000269|PubMed:27708256}.
FT   MUTAGEN     209    209       S->A: Abolishes phosphorylation by IKKB
FT                                and reduces cell growth.
FT                                {ECO:0000269|PubMed:19716809}.
SQ   SEQUENCE   235 AA;  26459 MW;  6393A907F5C2DDC4 CRC64;
     MNIRNARPED LMNMQHCNLL CLPENYQMKY YFYHGLSWPQ LSYIAEDENG KIVGYVLAKM
     EEDPDDVPHG HITSLAVKRS HRRLGLAQKL MDQASRAMIE NFNAKYVSLH VRKSNRAALH
     LYSNTLNFQI SEVEPKYYAD GEDAYAMKRD LTQMADELRR HLELKEKGRH VVLGAIENKV
     ESKGNSPPSS GEACREEKGL AAEDSGGDSK DLSEVSETTE STDVKDSSEA SDSAS
//
